Testosterone undecanoate compositions

US10561615B2 · kind B2 · utility

Assignee

• Lipocine, Inc. · US

Inventors

• Basawaraj Chickmath · Minneapolis, US
• Chandrashekar Giliyar · Plymouth, US
• Nachiappan Chidambaram · Salt Lake City, US
• Mahesh V. Patel · Salt Lake City, US
• Srinivasan Venkateshwaran · Salt Lake City, US

Key dates

• Filing date: Sep 29, 2014
• Grant date: Feb 18, 2020
• Expiry date: Dec 1, 2034

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K9/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure is drawn to pharmaceutical compositions and oral dosage forms containing testosterone undecanoate, as well as related methods of treatment. In one embodiment, the oral dosage form can include a therapeutically effective amount of testosterone undecanoate and a pharmaceutically acceptable carrier. The dosage form can be formulated such that, when measured using a USP Type II apparatus in 1000 mL of 8 wt % Triton X-100 in water at 37° C. and 100 rpm, the oral dosage form releases at least 20% more testosterone undecanoate after the first 120 minutes than an equivalent dose testosterone undecanoate containing oral dosage form without the pharmaceutically acceptable carrier.